

Abstracts: 109, 1501, 1593, 2548, 2533, 4010, 4021, 4131, 6057, 6510, 6527, 9022, S406, TPS1603

Media Toolkit

Penn Medicine at the 2022 American Society of Clinical Oncology Annual Meeting and Exposition

June 3 – 7, Chicago

June 2, 2022

Experts from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania will be presenting during ASCO's annual meeting from June 3-7 on the latest advances in solid-tumor targeting and treatment, including for pancreatic and non-small cell lung cancer, innovations in telehealth and text interventions, and strategies to expand diversity and equity.

Experts

Experts from the Abramson Cancer Center and Perelman School of Medicine are available to comment on a wide range of cancer research topics during the meeting in person, by telephone or email. To arrange interviews, please contact Caren Begun at caren.begun@pennmedicine.upenn.edu or 267-408-9196. Follow us on Twitter at [@PennCancer](https://twitter.com/PennCancer), [@PennMDForum](https://twitter.com/PennMDForum) and [@PennMedicine](https://twitter.com/PennMedicine).

Additional Highlighted Abstracts

- Diversity, Equity and Inclusion in Cancer
 - Association between state Medicaid policies and accrual of Black participants to cancer clinical trials (Abstract #[1501](#))
 - Racial and ethnic disparities in adherence and reported symptoms during routine collection of patient-reported outcomes (Abstract #[6510](#))
 - Variation in telemedicine usage in gynecologic cancer: Are we widening or narrowing disparities? (Abstract #[1593](#))
 - Site self-assessments and institutional strategies to advance equity (Abstract #[S406](#))
- Solid Tumors: Pancreatic Cancer
 - Distinct biosignatures associate with survival after chemoimmunotherapy in a randomized, three-arm phase II study in patients with metastatic pancreatic cancer (Abstract #[4010](#))
 - Phase 1, first-in-human study of the anti-HER2 CAR macrophage CT-0508 in subjects with HER2 overexpressing solid tumor (Abstract #[2533](#))
 - A randomized phase Ib/II study of niraparib plus nivolumab or ipilimumab in patients with platinum-sensitive advanced pancreatic cancer (Abstract #[4021](#))
 - A descriptive study on the treatment and outcomes of patients with platinum-sensitive, advanced, BRCA or PALB2 related pancreatic cancer who have progressed on rucaparib (Abstract #[4131](#))

- Circulating KRAS variant-specific shedding and association with survival in patients with metastatic pancreatic ductal adenocarcinoma receiving chemoimmunotherapy. (Abstract #2548)
- Non-Small Cell Lung Cancer (NSCLC)
 - Association of comprehensive molecular genotyping and overall survival in patients with advanced non-squamous non-small cell lung cancer (Abstract #9022)
 - First report of safety/tolerability and preliminary antitumor activity of CAN-2409 in inadequate responders to immune checkpoint inhibitors for stage III/IV NSCLC (Abstract #9037)
- Intervention and Prevention
 - Long-term effect of machine learning–triggered behavioral nudges on serious illness communication and end-of-life outcomes among patients with cancer: A randomized clinical trial (Abstract #109)
 - Association between up-front surgery and risk of stroke in U.S. veterans with oropharyngeal squamous cell carcinoma (Abstract #6057)
 - Saving TIME: Accuracy of a text intervention to minimize the time burden of cancer care (Abstract #6527)
 - Telehealth weight loss program for breast cancer survivors is feasible and acceptable: Preliminary results of pilot clinical trial (Abstract #TPS1603)

Related Links

- [Abramson Cancer Center](#)
- [Perelman School of Medicine](#)
- [University of Pennsylvania Health System](#)

MEDIA CONTACT:

Caren Begun

Senior Cancer Communications Officer

Perelman School of Medicine

University of Pennsylvania Health System

Cell: 267-408-9196

Email: caren.begun@pennmedicine.upenn.edu



Penn Medicine

Note: for interest in interviews with experts on data being presented, and expert opinion from leadership including Robert H. Vonderheide, MD, DPhil, director of the Abramson Cancer Center, please contact Caren Begun who is onsite and able to coordinate.